3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
18
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
3
Melanoma
3
Brain Neoplasms
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Neuroblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Colorectal Neoplasms
2
Advanced Cancer
2
Urologic Neoplasms
1
Unilateral Breast Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Multiple Myeloma
1
Interventions
Gemcitabine
39
Cisplatin
24
Oxaliplatin
15
pembrolizumab
12
Capecitabine
12
Fluorouracil
9
Leucovorin
7
Albumin-Bound Paclitaxel
7
lenvatinib
6
Radiofrequency Ablation
6
Panitumumab
6
130-nm albumin-bound paclitaxel
6
Irinotecan
5
Bevacizumab
5
durvalumab
4
Taxes
4
Nivolumab
4
Hepatectomy
4
Drug Therapy
4
tremelimumab
3
apatinib
3
Radiosurgery
3
Platinum
3
Injections
3
Floxuridine
3
Cetuximab
3
1,2-diaminocyclohexaneplatinum II citrate
3
trametinib
2
spartalizumab
2
sintilimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Cholangiocarcinoma
×
abemaciclib
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled